Histiocytosis and Treatment Targets
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 49
Special Issue Editor
Interests: ECD advocate; Histiocytosis; pharmacology; cardiac devices; cardiac hypertrophy; aortic stiffening; gene pathways; atrial fibrillation; ventricular tachycardia; HRV; COVID-19
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Histiocytosis encompasses intriguing rare blood cancer disorders characterized by the accumulation of tissue histocytes, often accompanied by inflammatory infiltrates. Histiocytosis is considered a clonal disorder with a high frequency of somatic mutations resulting in activation of the MEK–ERK signaling pathway. Recent breakthroughs in understanding the mitogen-activated protein kinase (MAPK) pathway have identified therapeutic strategies with targeted therapies for this pathway. However, the disease can still be difficult to manage in terms of efficacy for MAPK pathway targets in individual patients. Other considerations include access to costly medications, tolerability and toxicity. Hence, other pharmacological considerations are warranted, including new targets of combinational therapy. The cost of targeted therapy and equity are recurring themes for the patient. We invite authors to explore the intricate interplay between histiocytosis and pharmacology, with a focus on Langerhans cell histiocytosis, Erdheim–Chester disease and juvenile xanthogranuloma. The topics of interest may include, but are not limited to, gene pathway analysis of targeted therapy, health system models of therapeutic access to targeted therapy, complexity of RAS mutations as druggable targets, toxicity with targeted therapy, “drug holidays” and resistance. Join us in unravelling the mysteries of therapeutic targets and outcomes in histiocytosis.
Prof. Dr. Craig Steven McLachlan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- in silico
- histiocytosis
- ECD
- LCH
- pharmacology
